Results 251 to 257 of about 20,950 (257)

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

British Journal of Dermatology, 2013
Ka Papp
exaly  

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Annals of the Rheumatic Diseases, 2014
Iain B Mcinnes, Juergen Braun, Paul Emery   +2 more
exaly  

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

Annals of the Rheumatic Diseases, 2017
Juergen Braun, Xenofon Baraliakos, Atul Deodhar, Mrcp   +2 more
exaly  

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

Therapeutic Advances in Chronic Disease, 2018
Dario Kivelevitch, Alan Menter
exaly  

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

British Journal of Dermatology, 2015
exaly  

Secukinumab: A Review in Ankylosing Spondylitis

Drugs, 2019
exaly  

Secukinumab

Reactions Weekly, 2017
openaire   +1 more source